MAX and pancreatic neuroendocrine tumor: In addition, eight (7.3%) patients with MAX mutations did not have PCC, but two had ganglioneomas, one had abdominal ganglioneuroblastoma, one had pancreatic NET, one head and neck PGL, and three were asymptomatic carriers.